Cargando…

Evaluating cognitive profiles of patients undergoing clinical amyloid-PET imaging

Episodic memory impairment and brain amyloid-beta are two of the main hallmarks of Alzheimer’s Disease. In the clinical setting, these are often evaluated through neuropsychological testing and amyloid PET imaging, respectively. The use of amyloid PET in clinical practice is only indicated in patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loreto, Flavia, Gunning, Stephen, Golemme, Mara, Watt, Hilary, Patel, Neva, Win, Zarni, Carswell, Christopher, Perry, Richard J, Malhotra, Paresh A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244634/ https://www.ncbi.nlm.nih.gov/pubmed/34222867 http://dx.doi.org/10.1093/braincomms/fcab035

Ejemplares similares

Visual atrophy rating scales and amyloid PET status in an Alzheimer's disease clinical cohort
por: Loreto, Flavia, et al.
Publicado: (2023)

Using amyloid PET imaging to diagnose Alzheimer’s disease in patients with multiple sclerosis
por: Kolanko, Magdalena, et al.
Publicado: (2020)

A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease
por: Inglese, Marianna, et al.
Publicado: (2022)

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments
por: Hoang, Karen, et al.
Publicado: (2022)

Amyloid duration is associated with preclinical cognitive decline and tau PET
por: Koscik, Rebecca L., et al.
Publicado: (2020)

HEARING IMPAIRMENT, COGNITIVE PERFORMANCE, AND BETA-AMYLOID DEPOSITION IN THE ARIC-PET AMYLOID IMAGING STUDY
por: Deal, Jennifer A, et al.
Publicado: (2019)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
por: Rubinski, Anna, et al.
Publicado: (2020)

Systematic Evaluation of Kinetics and Distribution of Muscle and Lymph Node Activation Measured by (18)F-FDG- and (11)C-PBR28-PET/CT Imaging, and Whole Blood and Muscle Transcriptomics After Immunization of Healthy Humans With Adjuvanted and Unadjuvanted Vaccines
por: Win, Zarni, et al.
Publicado: (2021)

Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results
por: Largent, Emily A., et al.
Publicado: (2020)

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
por: Ossenkoppele, Rik, et al.
Publicado: (2022)

Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories
por: Ackley, Sarah F., et al.
Publicado: (2021)

Reasons for undergoing amyloid imaging among cognitively unimpaired older adults
por: Ryan, Mary M., et al.
Publicado: (2021)

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer’s Disease
por: Murray, John, et al.
Publicado: (2014)

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment
por: Chandra, Avinash, et al.
Publicado: (2019)

Software compatibility analysis for quantitative measures of [(18)F]flutemetamol amyloid PET burden in mild cognitive impairment
por: Pemberton, Hugh G., et al.
Publicado: (2023)

PT569. Association between cerebral amyloid deposition and cognitive function in geriatric depression: pilot study using amyloid PET
por: Kim, Hye-Geum, et al.
Publicado: (2016)

Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment
por: Pyun, Jung-Min, et al.
Publicado: (2021)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity
por: Pyun, Jung-Min, et al.
Publicado: (2021)

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition
por: Pontecorvo, Michael J., et al.
Publicado: (2017)

Patterns of Focal Amyloid Deposition Using (18)F-Florbetaben PET in Patients with Cognitive Impairment
por: Chung, Sung-eun, et al.
Publicado: (2022)

Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods
por: Collij, Lyduine E., et al.
Publicado: (2019)

Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients
por: Tomadesso, Clémence, et al.
Publicado: (2018)

Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging
por: Matías-Guiu, Jordi A., et al.
Publicado: (2016)

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
por: Doraiswamy, P M, et al.
Publicado: (2014)

Diagnosed Mild Cognitive Impairment Due to Alzheimer’s Disease with PET Biomarkers of Beta Amyloid and Neuronal Dysfunction
por: Hatashita, Shizuo, et al.
Publicado: (2013)

Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria
por: Triviño-Ibáñez, Eva María, et al.
Publicado: (2019)

Perfluoropolymer/Molecular Sieve Mixed-Matrix Membranes
por: Golemme, Gianni, et al.
Publicado: (2019)

Charge Mobility in Discotic Liquid Crystals
por: Termine, Roberto, et al.
Publicado: (2021)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

(18)F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment
por: Chun, Min Young, et al.
Publicado: (2022)

A Novel Auditory-Cognitive Training App for Delaying or Preventing the Onset of Dementia: Participatory Design With Stakeholders
por: Frost, Emily, et al.
Publicado: (2020)

False Memory and Alzheimer's Disease Pathology in Patients with Amnestic Mild Cognitive Impairment: A Study with Amyloid PET
por: Choi, Eun-Ji, et al.
Publicado: (2021)

Quantification of Brain β-Amyloid Load in Parkinson's Disease With Mild Cognitive Impairment: A PET/MRI Study
por: Garon, Michela, et al.
Publicado: (2022)

Predictive Scale for Amyloid PET Positivity Based on Clinical and MRI Variables in Patients with Amnestic Mild Cognitive Impairment
por: Chun, Min Young, et al.
Publicado: (2022)

Clinical Significance of Physical Frailty in Subjects With Subjective Cognitive Decline: A Prospective Study With Amyloid PET Data
por: Lim, Eun Ye, et al.
Publicado: (2023)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

COGNITIVE PERFORMANCE, EXERCISE, AND AMYLOID BURDEN: A RANDOMIZED CONTROLLED TRIAL
por: Watts, Amber, et al.
Publicado: (2019)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
por: Jeon, Seun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0jdrslfh5enf97qkehl8otan1s